Abstract
D r a f t

Introduction
Complementary and alternative medicine (CAM) is widely used in developing countries
where it contributes up to 80% of the healthcare needs of the people. It is also becoming more popular in developed countries due to the side effects and high cost of allopathic drugs.
World Health Organization has reported that about 38 to 75% of the people in Australia, Belgium, Canada, France, and the USA have used CAM at least once in their lifetime (WHO 2002) . Increasing global demand for CAM is expected to boost the medicinal plant raw drug trade from approximately 120 billion USD to 7 trillion USD by the year 2050 (Marichamy et al. 2014 ). Yet, frequent reports on species adulteration in traded raw drugs are major threat to the efficacy and safety of CAM (Stoeckle et al. 2011; Revathy et al. 2012; Ouarghidi et al. 2013; Seethapathy et al. 2014; Mishra et al. 2015) , which could ultimately affect the trade industry. Therefore, identification of species adulteration in traded raw drugs becomes essential to consumers as well as traders.
Species authentication is a challenging task as most of the raw drugs are traded in the form of dried, fragmented or powdered leaves, flowers, seeds, stem bark, roots, and other plant parts, which do not possess intact diagnostic characters required for morphological D r a f t 3 identification by Linnaean taxonomy. Alternative methods such as chemotaxonomy, chromatography, and microscopy, which were adopted for this purpose showed only limited success in species identification. Major limitations of these methods includes involvement of complex chemistries, lack of unique compounds, influence of environmental factors, plant's age, and geographical variations (Techen et al. 2014) . All these challenges can be largely overcome by using DNA barcoding, which does not rely on the morphology of plants, and therefore, is not affected by the above mentioned factors. Moreover, DNA barcoding can be done using live or dead tissue from any part of the plant at any stage of its life cycle. In fact, identification of species adulteration in traded raw drugs is one of the most useful applications of plant DNA barcoding. Though several chloroplast markers have been used for DNA barcoding of plants (Sucher and Carles 2008; Techen et al. 2014 ) the Consortium for the Barcode of Life Plant Working Group has recommended rbcL and matK as core DNA barcode markers for plants (CBOL Plant Working Group 2009 ).
The power of DNA barcoding to identify species has been demonstrated in several studies. Bruni et al. (2010) have demonstrated that DNA barcoding can be used for rapid and accurate identification of poisonous plant materials. Mattia et al. (2011) have employed a DNA barcoding approach for species identification in processed plant materials of commercial kitchen spices. Cornara et al. (2013) have successfully used DNA barcoding in a multidisciplinary approach for the identification of ingredients in commercial plant mixtures.
However, there are only a few DNA barcoding studies in which a large number of medicinal plant raw drugs and natural health products were tested for species adulteration (Kool et al. 2012; Wallace et al. 2012; Newmaster et al. 2013) . Such studies are very limited in India, which is endowed with about 7,500 recognized medicinal plants in various codified and noncodified systems of Indian medicine (Ved and Goraya 2008) . The current study, reports a large scale study on species adulteration in diverse traded medicinal plant raw drugs. A D r a f t 4 medicinal plant reference DNA barcode library was assembled for 521 medicinal plants using rbcL and matK markers, and subsequently used to identify species adulteration in 112 traded raw drugs collected from the markets.
Material and methods
Reference DNA barcode library
Plants for this study were selected from the medicinal plant list provided by National Medicinal Plants Board (NMPB), Government of India, available at http://nmpb.nic.in/. Leaf samples were collected from different localities in India, which includes botanical gardens, herbal gardens, cultivated, and natural fields. Collected samples were identified by plant taxonomists and their corresponding vouchers were deposited at the SRM University herbarium (SRMUH). DNA barcodes were generated for 400 medicinal plant species, and combined with DNA barcodes of 121 species from our previous studies (Purushothaman et al. 2014; Nithaniyal et al. 2014; Vassou et al. 2015) to create a larger reference DNA barcode library for medicinal plant species.
Collection of raw drug samples
Medicinal plant raw drugs are traded across India through various outlets such as wholesale markets, food stores, and pharmacies. We collected single plant raw drugs that contained only one ingredient as per the label. Vernacular names for the raw drugs were obtained from traded-medicinal plants database (http://envis.frlht.org/botanical_search.php) using botanical name search. Vernacular names in Tamil were used to collect the plant raw drugs from markets. Specifically, we collected 112 raw drug samples from eight markets in Tamil Nadu, India (Fig. 1, Table S1 ) of which 68 plant raw drugs were in the form of dried plant parts such as leaves, carved roots, seeds, rhizomes, fruits, and whole plants, and the remaining 44 were in the form of powders of known (leaf, bark, seed, fruit, and whole plant) or unknown origin. All voucher samples of raw drugs were deposited in the SRM University D r a f t 5 herbarium. Details of the plant raw drugs collected are provided in Table S1. (supplementary   data, Table S1 .).
Genomic DNA Isolation, PCR Amplification and DNA Sequencing
Total genomic DNA was isolated by following the protocol of Saghai-Maroof et al.
with minor modifications (Saghai-Maroof et al. 1984) . About 100 mg of sample was taken and ground using mortar and pestle by adding 500 µl of CTAB buffer (100 mM Tris-HCl, 1.4 M NaCl, 20 mM EDTA, 2% CTAB, 1% beta-mercaptoethanol, and 2% polyvinylpyrrolidone). Homogenized samples were transferred to 1.5 ml centrifuge tubes, incubated in water bath at 60 o C for 30 minutes. Samples were then extracted with equal volume of chloroform and centrifuged at 10,000 rpm for 10 minutes. The aqueous phase was transferred to 1.5 ml centrifuge tubes, precipitated by adding equal volume of ice-cold isopropanol, and centrifuged at 10,000 rpm for 10 minutes. The DNA pellet was washed twice with 70% ethanol, air-dried at room temperature, and dissolved in 100 µl TE buffer.
Genomic DNA suitable for PCR amplification was successfully isolated from all samples. Universal primer pairs were used for PCR amplification of rbcL (rbcLa-F and rbcLajf634-R) (Levin et al. 2003; Fazekas et al. 2008 ) and matK (matK-1RKIM-F and matK-3FKIM-R, Ki-Joong Kim, School of Life Sciences and Biotechnology, Korea University, Seoul, unpublished). PCR reaction mixture contained 1X buffer with 1.5 mM MgCl 2 , 0.2 µM dNTPs, 5 pmol primers, and 1 unit Taq DNA polymerase. PCR amplification was done in a thermal cycler (Eppendorf, Germany) using the following protocol: Initial denaturation at 95°C for 5 minutes, 30 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 1 minute, final extension at 72°C for 5 minutes, and hold at 16 o C. The PCR amplified products were purified using EZ-10 Spin Column PCR Purification Kit (Bio Basic Inc. Ontario, Canada). Sequencing of the PCR products was performed using Big-dye terminator chemistry in 3130xl Genetic Analyzer (Life D r a f t 6 Technologies, California, USA) by following the standard protocol as recommended by the manufacturer.
Data analyses and identification of traded raw drugs
Sequence quality was analyzed with Sequence Scanner Software v1.0 (Applied Biosystems, CA, USA) and full-length sequences were assembled using Codon Code Aligner, version 4.2.4 (CodonCode Corporation, MA, USA). Identification of traded raw drugs was done by comparing DNA barcodes obtained from the raw drug with the medicinal plant reference DNA barcode library. Species identification of the raw drugs was performed by best match method using TaxonDNA/Species identifier version 1.6.2 (Meier et al. 2006 ).
This method assigns a query sequence to its closest match based on the genetic divergence. 
Results
Assembly of reference DNA barcode library
We generated a reference DNA barcode library consisting of 1,452 barcodes from 521 medicinal plant species (1.64±1.01 and 1.13±1.24 barcodes per species for rbcL and matK, respectively), which was subsequently used for the purpose of identifying species adulteration in the medicinal plant raw drugs that were collected from the markets. The 521 medicinal plant species were taxonomically diverse representing 374 genera, 119 families and 44 orders. DNA isolation was successful for all the samples and purity of the genomic DNA was sufficient for the purpose of DNA barcoding as indicated by 100% PCR and sequencing success with rbcL marker. However, PCR and sequencing success rate was only D r a f t 7 60% for matK marker. Bidirectional sequencing yielded 94% full-length sequences for rbcL (607bp). In the case of matK, full-length sequences were obtained from 47% of the samples, and the size varied between 828bp and 858bp. Currently, the reference DNA barcode library contains 1,452 DNA barcodes from rbcL and matK markers. The size of the barcodes varies from 504bp to 607bp and 624bp to 858bp for rbcL and matK, respectively. All the DNA barcode data were submitted to BOLD under the accessions numbers SRM000170A to SRM000296A and SRM000670A to SRM000943C.
Species resolution of reference DNA barcode library
We calculated pairwise genetic divergence between species to evaluate the ability of rbcL and matK markers to differentiate medicinal plant species in the reference DNA barcode library. The rbcL marker differentiated 388 out of 521 species (74.4%) with the pairwise genetic divergence ranging between 0.2% and 19.0%. The matK marker differentiated 287 out of 318 species (90.2%) with the pairwise genetic divergence ranging between 0.2 and 21.0%. When these two markers were combined, 296 out of 318 species (93.0%) could be differentiated. However, in the tiered approach wherein the rbcL sequence acts as scaffold on which the matK sequence is placed for species differentiation, 450 out of 521 species (86.3%) were differentiated.
DNA barcoding of the traded raw drugs
Genomic DNA was successfully isolated from all 112 raw drug samples using a standard protocol. PCR amplification and sequencing of rbcL DNA barcodes were successful for all samples and chromatogram of the rbcL DNA barcodes did not show mixed peaks in any of the raw drug sample analyzed. Therefore, the recovered barcodes could be directly compared with those present in the reference DNA barcode library for species identification.
The DNA barcodes from 90 traded raw drugs (approx. 80%) showed the highest identity with expected species in the medicinal plant reference DNA barcode library. However, ten of them D r a f t 8 also showed the highest identity with other species in the same genus or closely related genus in the same family.
Identification of the species adulteration in traded raw drugs
DNA barcodes from the remaining 22 raw drugs (approx. 20%) showed 1.5 to 10.2% genetic divergence with expected species in the medicinal plant reference DNA barcode library, which strongly indicated species adulteration. DNA barcodes were searched against the non-redundant nucleotide database of NCBI and BOLD to establish their species identity.
The DNA barcodes from 15 raw drugs showed 100% identity with single species, and that from seven species showed 100% identity with multiple species from the same genus or different genera of the same family. Therefore, botanical identity could be established at species, genus, and family level for 15, 4, and 3 adulterated plants, respectively (Table 1 ). All 22 adulterant species belonged to different genera when compared with the species mentioned on the label, and 14 of them even belonged to a different family. The majority of traded raw drugs were in the form of powders, seeds, roots, and whole plants, and among them, adulteration was found to be the least within seeds (4.0%). Adulteration with roots, whole plants, and powders was 42.9%, 33.3%, and 22.7%, respectively. We then compared medicinal properties of the expected species and the adulterant species for the 15 raw drugs in which the adulterated plant materials were identified to species level. Eight adulterant species shared some but not all the medicinal properties of the expected species. The remaining seven adulterant species had no resemblance with the expected species in terms of the medicinal values, and some of them were even reported to be toxic (supplementary data, Table S2 .).
Species adulteration, presence of one species in place of the other, in traded medicinal plant raw drugs is a growing concern in the context of increasing popularity and demand for CAM throughout the World (WHO 2004) . Different terminologies such as adulteration, substitution, fraudulent substitution, admixture, mislabeling, contamination, filler, etc., are used to refer to species adulteration in raw drugs (Srirama et al. 2010; Wallace et al. 2012; Newmaster et al. 2013; Swetha et al. 2014; Kumar et al. 2015) . In the present study, a traded medicinal plant raw drug sample was considered to have species adulteration if DNA barcoding did not identify the species that was mentioned on the label, and the actual species found was referred to as an adulterant species. Analysis of 112 traded medicinal plant raw drugs revealed the presence of adulterant species in about 20% of the samples. Adulteration was frequent in dried roots, powders, and whole plants, which are more difficult to identify based on morphology. All adulterations were presumably in the form of complete replacement of one species for the other as indicated by the absence of characteristic mixed peaks. Interestingly, all adulterant species were from a different genus, and in some cases, even from a different family. Taxonomic analysis of controversial drug plants (Nair 2004) that are often found as adulterant species show that 78% of them belong to other genera and families. The conserved rbcL marker, which is capable of mostly genus level taxonomic discrimination but credited with good PCR amplification and sequencing success (Bafeel et al. 2012; Parmentier et al. 2013; Chen et al. 2014) would be sufficient to establish species adulteration in most of the traded raw drugs. However, ITS2 is evolving as a successful core or supplementary marker to increase species resolution and raw drug authentication cordifolia (Vassou et al. 2015) .
When adulterant species in raw drugs are used directly or in formulations, it is unlikely that the consumer will derive the same health benefits as expected from authentic species. In some cases, adulterant species is also claimed to possess the same medicinal properties as that of the authentic species. If so, fair practice would be to mention the correct name of that species on the label so that the consumer or the practitioner of the alternative medicine can take informed decision on using a particular raw drug. Alarmingly, some of the adulterant species are known to contain compounds that are toxic if consumed. For example, Z.
pentandra was found in place of B. diffusa, which was reported to cause abortion (Quattrocchi 2012 
Cardiospermum halicacabum (x).
Supplementary data Table legends   Table S1 . Details of the 112 traded medicinal plant raw drugs that were collected for the current study. 
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